Core Viewpoint - The Merck & Co., Inc. class action lawsuit alleges that the company and its executives made misleading statements regarding the company's revenue outlook and growth prospects for Gardasil, leading to significant stock price declines when the truth was revealed [3][4][5]. Group 1: Allegations of Misleading Statements - The lawsuit claims that Merck created a false impression of reliable information about its revenue outlook and growth of Gardasil while downplaying competition risks and drug approval developments [3]. - It is alleged that Merck's optimistic reports regarding growth and demand in China were not reflective of the actual situation, which showed diminished ability to drive demand for Gardasil [3]. Group 2: Stock Price Impact - Following the announcement on July 30, 2024, regarding a significant drop in shipments from its distributor, Merck's stock price fell nearly 10% [4]. - On February 4, 2025, after disclosing a 3% decline in Gardasil sales to $8.6 billion, Merck's stock price dropped more than 9% [5]. Group 3: Class Action Process - Investors who purchased Merck securities during the class period can seek appointment as lead plaintiff, representing the interests of the class [6]. - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect the ability to share in any potential recovery [6]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud cases, having secured $6.6 billion for investors in class action cases [7]. - The firm has a strong track record, being ranked 1 in securing monetary relief for investors in six out of the last ten years [7].

Core Viewpoint - A class action securities lawsuit has been filed against Merck & Co., Inc. due to alleged securities fraud affecting investors between February 3, 2022, and February 3, 2025 [1] Group 1: Lawsuit Details - The lawsuit aims to recover losses for Merck investors who were impacted by the company's misleading statements regarding expected revenue of $11 billion from Gardasil sales by 2030 [2] - The complaint highlights that Merck's optimistic forecasts for Gardasil's growth in China were based on the company's confidence in consumer activation and education efforts [2] - On February 4, 2025, Merck announced it would not meet the $11 billion sales target for Gardasil by 2030, citing a halt in shipments to China to reduce inventory due to lower-than-expected demand [2] Group 2: Stock Impact - Following the announcement on February 4, 2025, Merck's stock price dropped from $99.79 per share to $90.74 per share, representing a decline of over 9% in one day [2] Group 3: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until April 14, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 4: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Merck & Co., Inc. securities between February 3, 2022, and February 3, 2025, of the April 14, 2025, deadline to serve as lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Merck securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 14, 2025 [2] - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] Group 2: Case Background - The lawsuit alleges that throughout the Class Period, Merck provided investors with optimistic revenue expectations of $11 billion from Gardasil sales by 2030 while concealing adverse facts about demand in China [4] - Defendants reportedly made materially false and misleading statements regarding Gardasil's demand, leading to inflated inventory levels for its distributor, Zhifei [4]

Group 1 - iREIT+HOYA Capital focuses on income-producing asset classes that provide sustainable portfolio income, diversification, and inflation hedging [1] - Companies with strong shareholder returns often possess moat-worthy attributes derived from scale and barriers to entry, particularly in industries like pharmaceuticals [2] Group 2 - The article emphasizes the importance of defensive stocks with a medium- to long-term investment horizon [2]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Merck & Co., Inc. related to misleading statements about Gardasil's expected revenue and demand in China, with a deadline for investors to seek lead plaintiff status in a federal securities class action by April 14, 2025 [2][4]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $100,000 in Merck between February 3, 2022, and February 3, 2025, to discuss their legal rights [1]. - The complaint alleges that Merck and its executives violated federal securities laws by making false statements regarding Gardasil's revenue expectations and demand in China [4]. - The firm has recovered hundreds of millions of dollars for investors since its founding in 1995, indicating a strong track record in securities litigation [3]. Group 2: Financial Performance and Market Reaction - On February 4, 2025, Merck reported a 3% decline in GARDASIL/GARDASIL 9 sales to $8.6 billion and announced a temporary pause in shipments to China [5]. - Following the announcement, Merck's stock price fell by $9.05 per share, or 9.1%, closing at $90.74 per share [5]. Group 3: Class Action Details - The lead plaintiff in a class action is the investor with the largest financial interest who directs the litigation on behalf of the class [6]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [6].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Merck & Co., Inc. regarding a class action lawsuit related to misleading statements about the expected revenue from Gardasil sales, which has led to a significant decline in Merck's stock price [1]. Group 1: Allegations and Impact - The lawsuit alleges that Merck provided investors with material information indicating expected revenue of $11 billion from Gardasil sales by 2030, supported by optimistic forecasts about demand in China [1]. - On February 4, 2025, Merck announced it would not achieve the projected $11 billion in sales, citing a halt in shipments to China due to over-inflated inventories and lower-than-expected demand [1]. - Following this announcement, Merck's stock price dropped from $99.79 per share on February 3, 2025, to $90.74 per share on February 4, 2025, representing a decline of over 9% in one day [1]. Group 2: Next Steps for Shareholders - Shareholders who purchased shares of MRK during the specified class period are encouraged to register for the class action, with a deadline of April 14, 2025, to seek lead plaintiff status [2]. - Registered shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress [2]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [3]. - The firm seeks recovery for investors who suffered losses due to misleading statements or omissions that artificially inflated stock prices [3].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Merck & Co., Inc. for alleged misrepresentations regarding the demand for its vaccine drug Gardasil in China, impacting investor confidence and inventory levels [1][2]. Group 1: Lawsuit Details - The lawsuit represents investors who purchased Merck securities between February 3, 2022, and February 3, 2025 [1]. - Allegations include that Merck lacked visibility into the demand for Gardasil in China, leading to inflated inventory levels at its distributor, Zhifei [2]. Group 2: Legal Process - Interested parties wishing to serve as lead plaintiff must file by April 14, 2025, with the role involving directing the litigation on behalf of the class [3]. - Shareholders can remain absent class members without taking action, and all representation is on a contingency fee basis, meaning no fees or expenses are required from shareholders [3]. Group 3: Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented large public and private pension funds [4]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" and listed in The Legal 500 for sixteen consecutive years [4].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Merck To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Merck between February 3, 2022 and February 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 19, 2025 (GLOBE N ...

Core Viewpoint - A class action lawsuit has been filed against Merck & Co., Inc. for alleged violations of securities laws, specifically related to misleading statements about the demand for its product Gardasil in China and inflated inventory issues [1][4]. Group 1: Lawsuit Details - The lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - Investors who purchased Merck's securities between February 3, 2022, and February 3, 2025, are encouraged to participate in the lawsuit [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Allegations Against Merck - The complaint alleges that Merck made false and misleading statements regarding its consumer activation and education efforts for Gardasil, particularly in China [4]. - The company was overly optimistic about Gardasil's demand while concealing negative facts about actual demand and inflated inventory held by its distributor, Zhifei [4]. - As a result of these misleading statements, investors suffered damages when the truth about Merck's situation was revealed [4].

NEW YORK, Feb. 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Merck investors who were adversely affected by alleged securities fraud between February 3, 2022 and February 3, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form? ...